P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW

• M. Hanna,
• J. Chorazy,
• I. Iheanacho,
• B. Gorsh,
• P.F. Wang,
• P. Paka,
• S. Perera

Affiliations

M. Hanna

1 GSK, Collegeville, PA, USA

J. Chorazy

2 Evidera, Evidera, London

I. Iheanacho

2 Evidera, Evidera, London

B. Gorsh

1 GSK, Collegeville, PA, USA

P.F. Wang

1 GSK, Collegeville, PA, USA

P. Paka

3 GSK, Philadelphia, PA, USA

S. Perera

4 GSK, London, United Kingdom